

04/07/98
JCJ
447 U.S. PTO

91

Attorney Docket No.: 3556.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
"Proteins with Changed Epitopes and Methods for the Production
Thereof"
Applicant: Uffe Loevborg

Sir:

Express Mail Label No. EM165549275US

Date of Deposit April 7, 1998

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Formal Drawings
4. Executed Combined Declaration and Power of Attorney
5. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)

Miriam Kelly
(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EM165549275US
Date of Deposit April 7, 1998

Sir:

This is a request for filing a **divisional** application under 37 C.F.R. 1.53(b) of
Applicant(s): Uffe Loevborg

Title: Proteins with Changed Epitopes and Methods for the Production
Thereof

38 pages of specification 3 sheets of drawings

2 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$790.00

Total Claims: $16 - 20 = 0 \times 22 =$ \$0

Independent Claims: $1 - 3 = 0 \times 82 =$ \$0

Total Fee: \$790.00

Priority of application serial no. EP 90610072.2 filed on December 5, 1990 is
claimed under 35 U.S.C. 119. A certified copy thereof was filed in the prior application.

The benefit of application serial nos. 08/050,172 filed on April 16, 1993,
08/346,590 filed on November 29, 1994, respectively, in the U.S. and PCT/DK91/00382
filed on December 5, 1991 via the PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$790, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 7, 1998

Carol E. Rozek
Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

DRAFT COPY - DRAFT COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Serial No.: to be assigned

Group Art Unit: to be assigned

Filed: April 7, 1998

Examiner: to be assigned

For: Proteins with Changed Epitopes and Methods for the Production Thereof

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, before the first line, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of serial no. 08/346,590 filed November 29, 1994, which is a continuation of 08/050,172 filed April 16, 1993 which is a 35 U.S.C. 371 national application of PCT/DK91/00382 filed December 5, 1991 and claims priority under 35 U.S.C. 119 of application serial no. EP 90610072.2 filed December 5, 1990, the contents of which are fully incorporated herein by reference.--

IN THE CLAIMS:

Please cancel claims 1-23 without prejudice or disclaimer and add new claims 24-39.

--24. A method of producing a protein variant evoking a lowered immunogenic response in animals including man in comparison to the response evoked by its parent protein, whereby said protein is epitope mapped using immunological and proteochemical methods, epitopes

are determined, and at least one of said epitopes is changed through mutation of a DNA molecule coding for the expression of said parent protein or synthesis of a DNA molecule coding for the expression of said variant protein, said mutated or constructed DNA molecule subsequently being inserted into a vector for transformation of transfection into a suitable host, wherein said vector is functional or whereby said mutated or constructed DNA molecule is integrated functionally into the genome of said host, said protein variant is expressed in the host, and recovered.

25. The method of claim 24, wherein said protein is an industrial enzyme.
26. The method of claim 25, wherein said enzyme is a detergent enzyme.
27. The method of claim 26, wherein said detergent enzyme is a protease, lipase, cellulase, amylase or oxidase.
28. The method of claim 25, wherein said enzyme is a process enzyme.
29. The method of claim 28, wherein said process enzyme is an amylase, lyase, lipase or cellulase.
30. The method of claim 24, wherein said protein is a medicinal protein.
31. The method of claim 30, wherein said medicinal protein is a hormone or medicinal enzyme.
32. A protein variant produced by the method of claim 1.
33. The protein variant of claim 32, which is an industrial enzyme or a process enzyme.
34. The protein variant of claim 33, wherein the industrial enzyme is a detergent enzyme selected from the group consisting of proteases, lipases, cellulases, amylases and oxidases, and

the process enzyme is selected from the group consisting of amylases, lyases, lipases and cellulases.

35. The protein variant of claim 32, which is a medicinal protein.

36. The protein variant of claim 35, wherein the medicinal protein is a hormone selected from the group consisting of insulin, HCG and growth hormone.

37. The protein variant of claim 32, which is a medicinal enzyme.

38. The protein variant of claim 37, wherein the medicinal enzyme is factor V, factor VII or factor VIII.

39. The protein variant of claim 32, which is another protein selected from the group consisting of interleukins and interferons.--


REMARKS

This preliminary amendment is submitted simultaneously with the filing of the present divisional application. By this amendment, applicant has canceled claims 1-23 and replaced such claims with new claims 24-39. New claims 24-39 are based on original claims 1-7, 18 and 19. The claims as rewritten set forth the invention in language which more fully accords with U.S. practice and rules to assist the Examiner in his or her consideration of any differences between the claimed invention and the prior art. No new matter has been added by this amendment.

Early examination and favorable consideration of the above-captioned application is earnestly solicited.

Respectfully submitted,

Date: April 7, 1998



Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



Title: PROTEINS WITH CHANGED EPITOPE AND METHODS FOR THE PRODUCTION THEREOF

5

FIELD OF THE INVENTION

This invention relates to methods for modifying proteins, especially enzymes that are used industrially, and proteins 10 used in medicine, and the modified proteins produced thereby, compositions containing such protein variants, and the use of the variants in various fields, including medicine. According to the invention the proteins are epitope mapped using immunological and proteochemical methods and eventually their 15 amino acid sequence is changed through genetic engineering thereby changing their immunological activity in order to make them less immunogenic and thereby reduce the risk of provoking allergic responses in animals, including man, subjected to exposure to the enzymes of the present invention. 20

BACKGROUND OF THE INVENTION

25 Various proteins, such as enzymes are used increasingly in industry and householding. Being proteins they will be able to stimulate an immunological response in man and animals.

30 Other proteins, such as hormones are used increasingly in medicine for the treatment and/or diagnosis of various conditions of illness and disease, whereby these proteins are injected into or otherwise presented to the immune system of animals, including man.

35 Depending on the way of presentation the stimulation can lead to production of various types of antibodies, and to a cellular response too. Of these routes at least one, being the

one type of antibody can have adverse effect in man and animals. The production of IgE and maybe IgG4 can lead to an allergic state, giving symptoms like f.ex. rhinitis, conjunctivitis or other.

5

It cannot be excluded that other immunologically based adverse reactions will be seen with the increased use of these proteins.

10 These drawbacks in the use of proteins have been known for many years and various solutions have been used for solving these.

15 Within the field of industrial enzymes the most frequently used method for avoiding problems with allergic reactions from exposure to the products has been confectioning the enzymes in various ways by immobilizing, granulating and coating the enzymes thereby avoiding any release of the proteinaceous material during normal handling and storage.

20

However, this solution poses various problems in relation to bringing the enzyme into contact with the material with which it is meant to interact, such as bringing the enzyme into solution etc., and also some release of the enzyme may occur 25 provoking an allergic reaction in subjects sensitive to an exposure.

30 Within the field of medicine a much used method has been to use proteins of especially human or corresponding animal origin or at least of the same primary structure as the human (or the animal in question) protein.

35 This has proven to be successful in many instances, but it is not always possible to establish the existence of an animal equivalent to the protein in question, or it has been found that certain modified proteins possess certain advantages over the native protein. In such instances the risk of provo-

king an allergic response in the subject receiving treatment or being diagnosed exists.

Consequently a need exists for developing proteins that 5 provoke less or no allergic reactions, while still retaining their original activity to a degree where they still are functional and may be used according to their original intent.

10 Those parts of a protein molecule that are recognized and bound immunologically are called epitopes. For molecules in the range of f.ex. 30000 Daltons there might be as many 12 epitopes.

15 Epitopes are being bound by immunological cells and by antibodies. Some epitopes are more important than other, these are called major in contrast to minor epitopes.

It has been found that slight changes in the epitopes will 20 affect the binding strength in these bindings (Walsh, B.J. and Howden, M.E.H. (1989): A method for the detection of IgE binding sequences of allergens based on a modification of epitope mapping, Journal of Immunological Methods, 121, 275-280; Geysen, H.M., Tainen, J.A., Rodda, S.J., Mason, T.J., 25 Alexander, H., Getzoff, E.D. and Lerner, R.A. (1987): Chemistry of Antibody Binding to a Protein. Science. 135, 1184-90; Geysen, H.M., Mason, T.J. and Rodda, S.J. (1988): Cognitive Features of Continuous Antigenic Determinants. Journal of molecular recognition. 1, 32-41.

30 This may result in a reduced importance of such a changed epitope, maybe converting it from a major to a minor epitope, or the binding strength may even be decreased to the level of high reversibility, i.e. no efficient binding. This phenomenon may be called epitope loss.

35 The above investigations were all performed on synthesized

peptides mimicking the epitopes in question and variants thereof in order to establish the relative importance of the amino acid residues in the epitope being investigated, and consequently these investigations do not prove any effects to 5 the epitopes in their native environment as parts of the complete protein, where phenomena only found in the tertiary structure of the protein, such as folding or the establishment of salt bridges etc., are in function.

10

SUMMARY OF THE INVENTION

The object of the invention is to provide for methods for 15 selecting where in the amino acid sequence of a protein to modify in order to obtain protein variants evoking a reduced immunological response, and these protein variants.

The present invention consequently in a first aspect relates 20 to a method of producing protein variants evoking a reduced immunogenic response in animals including man in comparison to the response evoked by its parent protein.

For this the protein is epitope mapped using immunological 25 and proteochemical methods, and the various epitopes are determined and characterized.

Subsequent to this at least one of said epitopes is changed through mutation of a DNA molecule coding for the expression 30 of said parent protein, or through synthesis of a DNA molecule coding for the expression of said variant protein. this is performed by using well established techniques known in the art of protein engineering.

35 The mutated or constructed DNA molecule is subsequently inserted into a vector for transformation of transfection into a suitable host, wherein said vector is functional or

whereby said mutated or constructed DNA molecule is integrated functionally into the genome of said host, and the protein variant of interest is expressed in the host.

5 Finally the protein variant is recovered and purified.

In a second aspect the invention relates to the proteins produced by the above method. Under this aspect industrial enzymes, such as detergent enzymes, e.g. proteases, lipases, 10 cellulases, amylases, or oxidases, process enzymes, e.g. amylases, lyases, lipases, or cellulases, medicinal proteins, e.g. hormones, e.g. insulin, HCG, or growth hormone, or medicinal enzymes, e.g. factor V, factor VII, factor VIII, or other proteins, e.g. interleukins, or interferons, are of 15 special interest.

In a third aspect the invention relates to compositions comprising the proteins of the second aspect, such as detergent compositions, or compositions for use in preventive 20 and/or alleviating therapy and/or diagnosis of various conditions in the animal body, including man.

In a fourth aspect the invention relates to the use of such compositions in preventive and/or alleviating therapy and/or 25 diagnosis of various conditions in the animal body, including man.

30 BRIEF DESCRIPTION OF THE DRAWING

The invention will be explained and illustrated in further detail in the following parts of the specification including the specific examples and the appended drawing, wherein

35 Figures 1 to 6 show plots of the binding of a number of enzyme variants to a reference antiserum as a function of

their concentration

DETAILED DESCRIPTION OF THE INVENTION

5

According to the first aspect of the invention epitope mapping is used to locate and characterize the various epitopes functionally present in a protein. Thereafter this information is used for selecting which amino acid residues in the 10 epitopes should be changed.

When the changes have been implemented through the now well established techniques of genetic engineering, and the protein variants have been produced, immunological and proteo-15 chemical techniques are used to analyze the new protein variants and determine whether the changes have led to switches from major to minor epitopicity or even to epitope loss.

This information is again used to decide whether the protein 20 variant(s) produced correspond to demands established for the protein, or, whether more or other changes have to be implemented.

Through the invention it has thus been made possible to 25 produce proteins, especially industrial enzymes and medicinal proteins that will present a reduced immunologic, such as allergenic, potential risk to the environment and animals subjected to exposure to the protein(s) in question.

30 The protein or enzyme variants of the invention will therefore present lower risk to man (and animals) be it in the production, usage or to the environment.

35 In performing protein mapping the protein of interest (called the reference protein) and variants thereof, made by genetic engineering or by chemical modification, are used for the

production of antibodies. Antibodies can be polyclonal (like antisera) recognizing many epitopes in an antigen and cross reacting with other often related antigens, monospecific recognizing a single antigen, epitope monospecific recognizing a single epitope, or monoclonal recognizing a single epitope and produced through fusion of cells producing the antibody and immortal cells, such as carcinoma cells.

Polyclonal antibodies will react to the protein antigen in a polyspecific manner, i.e. there will be many specificities each reacting with each own epitope in the antigen or showing different reactivities to different related epitopes. Also, polyclonal antibodies will often cross-react with related antigens. Monospecific antibodies are polyclonal antibodies isolated according to their specificity for a certain antigen, such monospecific antibodies will normally only be specific to a very limited number of epitopes, and often only specific to one epitope.

Epitope mono specific antibodies are polyclonal antibodies isolated according to their specificity for a certain epitope. Such epitope mono specific antibodies will only be specific to one epitope, but they will often be produced by a number of antibody producing cells, and are consequently not identical.

Monoclonal antibodies are epitope specific antibodies produced by the now well established technique of cell fusion between an antibody producing cell and an immortal cell. All monoclonal antibodies produced by one clone are identical.

The antibodies produced can bind the immunizing protein antigen. Furthermore, if fully or partially identical epitopes exist in the other proteins, the antibody will be able to bind to these too. If there is complete identity the recognition and binding will be identical. If there is partly identical epitopes the recognition will be different and the

binding strength will be lower. If the epitope is not present the antibody will not bind.

The mapping using polyclonal antibodies, can be divided into 5 two phases:

- i) Measure the reactivity of the antibody preparations toward all proteins of interest.
- ii) Measure the reactivity left over to react with one antigen after reaction with another.

10

The results from (i) will provide information about the immunogenic and allergenic potential of the variants investigated. According to this some variants exhibiting a reduced potential could prove to be interesting protein variants, 15 whereas others exhibiting an increased potential are deemed not to be interesting from an immunological viewpoint.

The results from (ii) will provide information concerning:

- iia) changes in epitope(s) showing which epitopes are 20 more or less immunogenic/allergenic.
- iib) loss of epitope(s) (even the highest concentration of one antigen will not eradicate all reactivity to reference antigen), or
- iic) establishment of new epitope(s) (even the highest 25 concentration of reference antigen will not eradicate all reactivity to a variant).

From this information it can be decided which variants can be used for the production

30

The selected protein variants may be produced by methods which by now are well known to the person skilled in the art of protein engineering, and described in numerous publications, such as International Publication No. WO/06279 (NOVO 35 INDUSTRI A/S), and International Patent Application No.

PCT/DK90/00164 (NOVO-NORDISK A/S) for both of which relevant sections are hereby incorporated in their entirety by refe-

rence.

EXAMPLES

5

The reference protein antigen chosen was SP436, a variant of the alkaline protease, subtilisin 309, whose construction and production is described in detail in the above mentioned International Publication No. WO/06279 (NOVO INDUSTRI A/S), 10 where it was designated (i). The SP436 variant comprises in respect of the wild type subtilisin 309 two changes in the amino acid sequence, i.e. G195E+M222A. International Patent Application No. PCT/DK90/00164 (NOVO-NORDISK A/S) shows the production of further variants made by genetic engineering. 15 The wild type enzyme is produced by normal fermentation, and the antibodies are polyclonal from rat.

The SP436 molecule is a protein comprising 269 amino acid residues, and it has in comparison to the well known sub- 20 tilisin BPN' 6 deletions. For further reference to the amino acid sequence of various subtilisin reference is again made to International Publication No. WO/06279 (NOVO INDUSTRI A/S), and International Patent Application No. PCT/DK90/00164 (NOVO-NORDISK A/S), wherein the amino acid sequences for a 25 number of proteases, a numbering system for subtilisin enzymes based upon the sequence of the subtilisin BPN', and a notation for indicating changes in the amino acid sequences are indicated. The numbering and notation therefrom will be followed throughout this specification and appended claims.

30

IMMUNIZATIONS.

Rats were selected as test animal due to the fact that according to the literature these are the only normal laboratory animal that are capable of binding human IgE onto its mast and basophile cell membranes, and at the same time having IgE

that will bind to human mast and basophile membranes.

The animals were divided into 12 groups each of 3 rats. For the immunizations the wild type (wt) subtilisin 309 and 11 variants thereof were selected. These are indicated in TABLE I below:

TABLE I
Subtilisin 309 variants used for immunization

10

	Grp No.	"Variant"	Adjuvant	Change in respect of wt
	1	SP436	Freund	G195E+M222A p - u u
15	2	S001	-	G195E p -
	3	S003	-	R170Y + p
20	4	S005	-	K251E + -
	5	S015	-	K235L + u
	6	S026	-	E136R - +
25	7	S033	-	E271Q - p
	8	S006	-	H120D + -
	9	S020	-	H120D+R170Y+G195E+K235L+K251E + - + p p - + u + -
30	10	S023	-	*36D+H120D+R170Y+G195E+K235L m - + - + p p - + u
	11	S028	-	D181N - p
35	12	WT	-	

-: negatively charged

+: positively charged

p: polar

40 u: unpolar

m: missing(deletion)

The injected quantity was invariably 30 μ g/animal/immunization. Each animal received 6 injections.

All 12 selected proteins were injected once in Freunds Complete Adjuvant, once in Freunds Incomplete Adjuvant and four times in NaCl 0.9%.

5 Blood was harvested one week after each immunization except for the final exsanguination, which followed 5 days after the last immunization.

After clotting, the sera from all three animals in each group 10 were pooled .

The analytical work described in the present report was on the 12 sera pools after the third blood harvest.

15

ANALYSIS.

The analytical work was performed in two series of analysis, A and D, both of which are ELISA techniques.

20

Series A:

One protein is used for coating the wells of one or more 25 ELISA-plates. This protein can be the native (wildtype) or a variant.

The 12 different sera pools in this analysis are incubated in the coated wells. The sera have all been raised against different proteins. If the variants are similar the sera are 30 expected to be similar in their reactivity pattern too. Each sera pool is tested in a dilution series in its own series of wells.

The potential binding of rat antibodies is visualized through 35 binding of peroxidase labelled anti-rat antibodies.

If rat antibodies were bound to the enzyme coating, they will

be bound in proportional manner by the peroxidase labelled anti-rat antibodies.

The presence of colour in this way gives a proportional 5 visual and measurable indication of presence of enzyme specific rat antibodies.

In a short step by step sequence the setup is:

- 10 1) Enzyme coating of solid phase.
- 2) Albumin blocking of residual binding spots on solid phase.
- 3) Incubating sera in dilution series, enzyme active anti-bodies being bound to the coated enzyme.
- 15 4) Peroxidase labelled anti rat(IgX) antibodies.
- 5) Development of colour.
- 6) Determination.

The 12 sera groups were tested for reactivity towards one 20 kind of protein (i.e. wt or variant) according to the above set-up. One by one different proteins were tested with the 12 sera groups.

The response was compared to the sera group originally immunized with the given protein, i.e. the reference.

The results give information on antibody recognizability of the individual proteins. Division can be made into three kinds of reactivity relative to the reference, i.e. same/higher/lower reactivity. See TABLE II below. Because of the assay design the phenomena of epitope loss and/or epitope change (to give a decrease in binding strength) are indistinguishable from each other.

The IgG response (TABLE II) shows three effects :

- 1) Each sera group (except anti-SP436) reacts stronger with its own immunogen than with any of the other. Especially 5 sera no 12 (anti-wt) show dramatic lower response to other proteins.
- 2) Some sera give in general higher responses than other.
- 10 This last feature can become very important together with the IgG and IgE distribution. Anyhow, it cannot be excluded to belong to some individuality in the responding animals. Such a feature is often expressed when only few animal sera are pooled (like in this case, three).
15
- 3) There is a heteroclitic effect for each of the tested proteins except S023. This means that sera from animals immunized with a protein that is not the test protein, will react stronger than the sera coming from animals 20 immunized with the test protein (horizontal values).

This is a characteristic feature also seen in work with small synthesized peptides that are used to produce antibodies to native (larger) protein. Here it is explained by differences 25 in conformation being in favour of the native molecule.

The IgE response (TABLE II) show effects comparable to (1), (2), and (3) mentioned for the IgG response.

30

Switch from one immunizing protein to another similar protein will for all except SP436 give lower IgG and IgE response. Switch from SP436 to another will increase this very signal, but only to a level comparable to the ones otherwise seen.

35 Furthermore there is a heteroclitic effect, which will be further discussed in connection with the following series D.

SERIES A :

Selected seras were tested with one and the same variant in each analysis. The variants were used for solid phase coating 5 at a concentration of 50 μ g/ml (phosphate buffer), this gave a near-monolayer immobilization. Residual binding spots on the surface were blocked by bovine serum albumin (=BSA).

Sera were tested in dilution series, first dilution 20 to 800 10 times, depending on sera strenght, and from this dilution in two-fold series. Phosphate buffer including blocking agent BSA and detergent.

Tracing performed by bound antivariant-antibody by mouse- 15 anti-rat antibodies that are conjugated to peroxidase. (Kem-En-Tec cat. no. Y 3300 diluted 1000x in same buffer as used for seras).

Visualization was obtained through enzymatic reaction of 20 peroxidase on OPD-substrate that is turning colored proportionally to peroxidase present, which is proportional to rat anti variant antibodies present.

Sera having high potential for reaction will give higher 25 response than others, and this will make estimation of strenght and mutual reactivity possible.

4.A.4. SERIES A, analysis 2+3

30 Analysis was performed as decribed under methods. Calculation of dilutions giving equal response, and "normalizing" these to the reference (i.e. the reaction of the individual sera with its immunising variant).

35 A low figure means the sera cannot be diluted as much as the reference, and a high figure that the sera can be diluted more than the reference. 49 therefore means that the serum

can be diluted only 0.49 times the reference reaction, e.g. 490x for the sample in comparison to the reference 1000x.

Results from these experiments are indicated in TABLE III
5 below:

TABLE III

	SERIES A (analysis 2 + 3)			DATA EXTRACTION					
						-			
AMINO ACID				FORWARD		REVERSE		RE- SPONSE	
EXCHANGE :				EXCHAN- GE:		EXCHANGE		TYPE :	
G195E				53			53		A
R170Y				84			65		A
D181N				164			24		B
K235L				114			56		B
E136R				80			53		B
E271Q				96			48		B
H120D				100			36		B
E251K				59			91		C

	G195E+M222A		67			49			A
	E195G+R170Y		126			77			B
	E195G+E136R		106			50			B
5	Y170R+E136R		75			79			A
	E251K+H120D		91			90			A
	E251K+D181N		134			74			B
10	E251K+E271Q		118			59			B
	Q271E+H120D		73			137			C
	D120H+D181N		137			71			B
15	D120H+E271Q		137			73			B
	N181D+K235L		79			128			C
20	E195G+A222M+ R170Y		70			65			A
	E195G+A222M+ E136R		70			59			A

	H120D+G195E+K235L+ K251E	89			95			A
	H120D+R170Y+K235L+ K251E	109			61			B
5	*36D+H120D+R170Y+ G195E	56			103			C
	*36D+R170Y+G195E+ K235L	40			82			C
10								
	H120D+R170Y+G195E+K235L+ K251E	90			45			B
	*36D+H120D+R170Y+G195E+ K235L	73			19			B
15	H120D+R170Y+A222M+K235L+ K251E	72			82			A
	*36D+H120D+R170Y+G195E+ K235L, E251K	76			82			A
20	R136E+H120D+R170Y+G195E+ K235L+K251E	75			73			A
	Q271E+*36D+H120D+R170Y+ G195E+K235L	50			95			B
25	D36*+D120H+Y170R+E195G+ L235K+D181N	117			41			B

	forward exchange : amino acid exchange as listed to the left.										
	reverse exchange : amino acid exchange opposite to the listed.										
5											
	type : A = exchanges gives nearly equal effect in both directions.										
		B = the reverse exchange is more important									
		C = the forward exchange is more important									
10											
	for all : if different from 100 this amino acid position is included in an epitope.										
	if <100 the epitope change means need for more antibody to give a response equal to the reference reaction.										
15											
	if >100 the epitope change means that there is a heteroclitic effect (affinity increase to this epitope).										

The interpretation of these results are discussed in detail
20 below in the concluding remarks.

Series D:

Again one protein was used for coating the wells in ELISA
25 plates. Furthermore only one sera pool was tested as the

reference. This serum was tested in only one dilution.

Before the sera were added to the coated wells, they were preincubated with the wild type or variant of the protein in 5 another set of wells.

In these other wells dilution series of wild type or variants were incubated with the same concentration of the reference. Each well therefore contained serum plus either wild type or 10 variant in a specific dilution from a dilution series.

The protein concentrations, were selected to assure a surplus of antigen in one end of the dilution series, and nearly no reaction in the other end. Consequently the protein can in 15 some wells block all rat anti-protein reactivity, if it corresponds in specificity. In other wells more and more rat antibody will remain unreacted. If the co-incubated protein is very different from the one used to produce the rat anti-bodies, unreacted antibodies will remain in all wells, in- 20 dependent of the concentration used.

After the co-incubation of sera plus diluted proteins, the reacted mixture was transferred to the coated wells.

25 If rat antibody activity is left over it will bind to the coated protein in the wells, and eventually the rat antibodies are bound by peroxidase labelled anti rat(IgX) antibodies, and development performed as above in Series A.

30 The results in this assay indicate whether the co-incubated protein is related to the coated or not. Both with respect to epitope identity (partly or fully) or epitope presence.

The variants used in this series are indicated below in TABLE 35 IV:

TABLE IV

Subtilisin 309 variants used in Series D

Changes in amino acid sequence compared to WT:

	WT	
5	SP436	G195E+M222A
	SP458	M222A
	S001)	G195E
	S003)	R170Y
	S005)	K251E
10	S006)	H120D
	S012)	R170Y+G195E+K251E
	S015)	K235L
	S019)	H120D+R170Y+G195E+K235L
	S020)	H120D+R170Y+G195E+K235L+K251E
15	S021)	*36D
	S022)	*36D+R170Y+G195E+K251E
	S023)	*36D+H120D+R170Y+G195E+K235L
	S024)	*36D+H120D+R170Y+G195E+K235L+K251E
	S025)	*36D+H120D+G195E+K235L
20	S026)	E136R
	S027)	E89S
	S028)	D181N
	S033)	E271Q
	S046)	Y209L

25

One sera group was used per assay, consisting of 22 subassays. In each sub-assay the sera were absorbed in liquid phase with wt or one of the variants in a dilution series. Finally the remaining antibodies were tested towards one and 30 the same protein all over.

Each sub-assay therefore results in removing antibody reactivity and estimating what is left over. In this set up one sera group is being absorbed with all 21 proteins, and finally 35 tested with the same type originally used for immunization.

Loss of epitopes in the absorbed protein compared to the tested protein will mean positive results even with the highest concentration of absorbing protein. As indicated in Figs. 1 to 6 the plots will for such variants level off not reaching the full effect seen in the reference absolute absorbtion.

Change of epitopes can mean lowering of binding strength. Therefore the sub-assay plots will be positioned different on the concentration axis, giving a titer difference in comparison with the reference absolute absorbtion.

So far only antisera to SP436 have been tested.

15 In Figures 1 through 6 the effect of absorbtion is plotted. The first well is without any variant or wt to absorb, i.e. an internal control. The following wells contain increasing concentrations of absorbing protein.

20 There is basically two types of plots. One is with decreasing values all over. Another is levelling off, leaving some response even in the presence of the highest concentration of absorbing protein. The first type will correspond to change of epitopes, whereas the second type will correspond to loss 25 of epitope (meaning a general lowering of binding energy, enabling a high degree of reversibility in antibody binding).

From Figures 1 through 6 it is obvious that the following S numbers "level off" : S003, S012, S019, S020, S022, S023, 30 S024 and S026. S026 contains the variant E136R and is the only variant in that position tested, therefore S026 is not included fully in the evaluation.

In TABLE V the effect of absorbtion is listed for all 21 35 proteins including the reference SP436 sorted in three parts.

The first part gives the effect of an amino acid change in

position nos. 195 and 222, and combinations with other single position changes.

The second part gives change of position no. 170 in combination with all other tested changes.

The third part gives change of position no. 251 in combination with all other tested changes.

10 The test serum was serum group no 1 (anti-SP436).

Results are measured as titer at one fixed read-out value, and recalculated to the absorbing capacity relative to the reference (in percent).

TABLE V

SERIES D, coat: SP436, sera group no. 1

All values are relative to sera group no 1 (= ref.).

All values are absorbance capacity relative to the reference.

5

Variant	IgG	IgE	Amino acid exch.
	v.40NSVU	v.40NSVU	rel. to SP 436
SP458	70	59	195
S001	70	87	222
10 WT	9	10	195, 222
S021	27	31	36, 195, 222
S027	104	380	89, 195, 222
S006	26	30	120, 195, 222
S026	0	0	136, 195, 222
15 S003	26	40	170, 195, 222
S028	102	220	181, 195, 222
S046	120	150	195, 209, 222
S015	30	36	195, 222, 235
S005	74	67	195, 222, 251
20 S033	74	29	195, 222, 271
S003	26	40	170, 195, 222
S012	14	20	170, 222, 251
S019	23	125	120, 170, 222, 235
25 S020	20	88	120, 170, 222, 235, 251
S022	4	11	36, 170, 222, 251
S023	4	4	36, 120, 170, 222, 235
S024	2	6	36, 120, 170, 222, 235,
251			
30			
S005	74	67	195, 222, 251
S012	14	20	170, 222, 251
S020	20	88	120, 170, 222, 235, 251
S022	4	11	36, 170, 222, 251
35 S024	2	6	36, 120, 170, 222, 235,
251			

RESULTS OF SERIES D.

Taking amino acid change one by one from TABLE V, absorbtion capacity being compared to the reference :

5 (ND = not distinguishable in present set-up)

No. 36:

	with 195+222 (S021)	ND
	with 170+222+251 (S022)	ND
10	with 120+170+222+235 (S023)	absorb less IgE
	with 120+170+222+235+251 (S024)	absorb less IgE

No. 89:

	with 195+222 (S027)	absorb more IgG , and absorb much more IgE
--	---------------------	---

15 No. 120:

	with 195+222 (S006)	ND
--	---------------------	----

no. 170:

	with 195+222 (S003)	ND
--	---------------------	----

no. 181:

20	with 195+222 (S028)	absorb more IgG, and absorb much more IgE
----	---------------------	--

No. 195:

	alone (SP 458)	absorb little less IgG, and absorb little less IgE
--	----------------	--

25	with 222 (SP 436)	absorb much less IgG, and absorb much less IgE
----	-------------------	--

No. 222:

30	alone (S001)	absorb little less IgG, and absorb little less IgE
----	--------------	--

No. 235:

	with 195+222 (S015)	ND
--	---------------------	----

35 No. 251:

	with 195+222 (S005)	absorb little more IgG, and absorb little more IgE
--	---------------------	--

	with 36+120+170+222+235 (S024)	ND
--	--------------------------------	----

40 no. 271:

	with 195+222 (S033)	absorb more IgG
--	---------------------	-----------------

The results must be compared with data in TABLE VI, where the inter-atomic distances between C_{α} 's are listed.

The epitope size is typically 10-15 Å in radius, and the 5 amino acids are exposed like in a field.

Combining this information with a 3-dimensional (3D) view, it will be possible to estimate which amino acids belong to the same epitope, and therefore will be bound by the same antibody.

TABLE VI
INTERATOMIC DISTANCES BETWEEN C_{α} 's in Å

AA no.	36	89	120	136	170	181	195	209	222	235	251	271
36	0	13,6	18,2	23,5	27,3	26	30,6	8,5	15,6	24,3	29,7	28,6
5	89	13,6	0	9,9	25,9	26,8	27,6	28,4	18,3	18,5	12,6	23,3
120	18,2	9,9	0	18,4	20,3	27,8	21,6	24,4	19,5	8,5	17,6	20,2
136	23,5	25,9	18,4	0	9,4	29,8	14,3	30,6	22,7	24,5	22,1	32
170	27,3	26,8	20,3	9,4	0	22	5,9	28,6	17,8	23,7	16,4	27,2
181	26	27,6	27,8	29,8	22	0	20,5	20,9	11,1	26,5	18,9	19,3
10	195	30,6	28,4	21,6	14,3	5,9	20,5	0	31	18,9	23	12,5
209	8,5	18,3	24,4	30,6	28,6	20,9	31	0	12,8	27	29,7	27,2
222	15,6	18,5	19,5	22,7	17,8	11,1	18,9	12,8	0	20,9	18,4	19,6
235	24,3	12,6	8,5	24,5	23,7	26,5	23	27	20,9	0	14,2	13,4
251	29,7	23,3	17,6	22,1	16,4	18,9	12,5	29,7	18,4	14,2	0	12,8
15	271	28,6	20,7	20,2	32	27,2	19,3	24,4	27,2	19,6	13,4	12,8
												0

Distances to/from no 36 are estimated as mean of (35 + 37) as the subtilisin 309 database does not include 3D coordinates of no 36 (not present in wt).

Initially nos 120 + 235 seem to cooperate in one epitope, and nos 195 + 251 in another epitope.

Furthermore nos 89 and 181 both will give much higher absorption of both IgE and IgG. No 251 little more of both, and no 271 little more of IgG.

Amino acid no 170 is changed in all the other cited nos., - leading to loss of epitope. Even the highest concentration of 10 these proteins will not remove all antibodies from the preparation.

This single epitope accounts for approximately 30 % of the reactivity, therefore it can be expected that the total 15 number of epitopes is low.

Also, it seems as if position 136 is connected with a major epitope (cf Fig. 4). Since S026 is the only variant wherein position 136 is changed, a definite conclusion must await 20 further study.

In TABLE VII below the probability for pairs of positions investigated here belonging to the same epitope is indicated

PROBABILITY FOR BEING IN THE SAME EPITOPE (<9.9 Å: high, 10-15 Å: medium)												
AA no.	36	89	120	136	170	181	195	209	222	235	251	271
36		medium					high					
5	89		high								medium	
												high
												high
120				high				medium				
136					high							
170						high						
181							medium					
10	195							medium				
									medium			
209										medium		
222											medium	
235												medium
251												medium
15	271											

From the above the following amino acid residues are selected for being changed in order to influence the immunological potential of subtilisin 309.

5 non-polar: 129, 131, 151, 152, 162, 168, 169, 172, 174,
175, 176, 194, 196,

polar: 127, 128, 130, 153, 154, 161, 163, 167, 171,
173, 193, 195,

charged: 136, 170, 186, 197, 247, 251, 261,

10

It is expected that changes in the charged amino acid residues will entail the greatest effect on the immunological potential of subtilisin 309.

15

Concluding remarks

SERIES A, the "data extraction" pages, TABLE III, list results from amino acid (AA) exchanges both ways i.e. there 20 are sera towards both variants in TABLE III, and these have been tested with their immunogen and other variants comprising changes in the same position(s).

Looking at changes from WT to a variant the following effects 25 are seen:

In the following the terms "essential", "critical", and "present" are used in connection with the amino acids in specified positions. These expressions have the meanings as 30 defined in Geysen et al. Science 135 (1987) 1184-90.

I. AA no. 120 is not "essential" in WT but becomes so in the variant.

35 AA no. 235 same as for 120 !
AA no. 271 same as for 120 !

II. AA no. 251 is "essential" in WT but not in variant.

III. AA no. 181 is showing heteroclitic effect in change D181N and is "essential" in backwards change N181D.

IV. AA no. 136 is giving big impact on response both ways of exchange.

AA no. 170 same as for 136.

AA no. 195 same as for 136.

10 The following exchange data can be segmented in more or less two groups (of 13 and 11 respectively) :

V. Rows 9, 11, 12, 13, 14, 15, 17, 19, 20, 21, 26, 27 and 32 exhibits effects that would be expected from the calculated accumulated effects in single mutations.

VI. Rows 10, 16, 18, 22, 23, 24, 25, 28, 29, 30, and 31 exhibit effects that would be not expected from calculated accumulated effects in single mutations.

20 It is noted that V. and VI. have been calculated without including AA no. 36, as there are no two-way data on this change. Therefor rows 24, 25, 27, 29 and 32 may in subsequent calculations including AA no. 36 exchange come out differently.

25 All AA's with data both ways line up as participants in some epitope. Their impact on recognition and binding by antibodies are largely different, but none are without any effect.

Groups I. and II. illustrate how some AA's are non-essential, whereas other in the same positions are essential.

35 From this it seems as if the tested changes in AA's 120, 235 and 271 create essential AA's, maybe even epitopes in the variants.

Also, it seems as if change of no 251 removes an essential AA.

5 This may in humans lead to a reduced allergenic reaction to the new variant as compared to the reaction to the wild type enzyme. After production of new antibodies towards the variant molecule, there may still be a low reaction that anyhow should be restored with full strength upon switch back to WT
10 exposure (both by anti-WT and anti-variant antibodies).

The most interesting group is III. where change of no..181 gives a heteroclitic effect (i.e. the anti-WT sera reacts stronger with the variants than with its own WT immunogen),
15 and this AA seems to be essential to the anti-variant sera.

Therefore this seems to be a very important position, which upon change can create increased response, not only in individuals that are exposed to the molecule on a first-time-
20 basis, but also individuals already having antibodies towards the WT enzyme can be expected to react even stronger with the variant.

This means that from an immunological view a change in this
25 position should be avoided.

The group IV. shows changes providing antisera that both ways react strongest with their own immunogen. A change in both ways exhibits decreased response, and the responses are restored upon returning to their own immunogen.
30

This may in humans mean an immediate lowering of response upon switch to variant, but as new anti-variant antibodies appear the response may be restored.

From an immunological viewpoint these changes seem to be neutral or even beneficial.

The remaining rows in Table III partly confirms the above, and partly illustrate that simple accumulation of effects cannot be expected in multiple AA exchange variants. Further analysis is needed to confirm any accumulation of immunological effects.

Using molecules wherein a single or a few amino acids have been changed the following effects were found:

- 10 1. In specific positions certain amino acids seems not to be essential to the epitope, whereas other may be.
- 15 2. In specific positions all tested amino acids seem to be essential to the epitope.
- 20 3. Exchange of one amino acid for another can give a heteroclitic effect. Furthermore the new amino acid may be essential to the "variant" molecule.
- 25 i No change immediately, but shortly later an increased response. Upon switch to exposure to molecule of origin the response is restored.
- 30 ii Lowering of the response upon change. Upon switch back to exposure to molecule of origin restoration of response.
- 35 iii Increase in response upon change. Upon switch back to exposure to molecule of origin an immediate drop is seen, that finally resumes the original strength of response before the change to the variant.
- iv Initially a drop in response, that is being restored.

Upon switch back to molecule of origin a drop in response that very soon is being restored.

From an immunological view the preferred switch will be of 5 the group II type, but also a group IV type of change is acceptable.

Although the present invention has been illustrated in connection with certain specific embodiments, this is in no way 10 to be construed that it should be limited to these embodiments, the invention being defined by the appended claims and the whole of the specification.

EPO EPO EPO EPO EPO EPO

PATENT CLAIMS

1. A method of producing a protein variant evoking a lowered immunogenic response in animals including man in comparison to the response evoked by its parent protein, 5 whereby said protein is epitope mapped using immunological and proteochemical methods, epitopes are determined, and at least one of said epitopes is changed through mutation of a DNA molecule coding for the expression of said parent protein or synthesis of a DNA molecule coding for the expression of 10 said variant protein, said mutated or constructed DNA molecule subsequently being inserted into a vector for transformation of transfection into a suitable host, wherein said vector is functional or whereby said mutated or constructed DNA molecule is integrated functionally into the genome of 15 said host, said protein variant is expressed in the host, and recovered.

2. The method of claim 1, wherein said protein is an industrial enzyme.

20

3. The method of claim 2, wherein said enzyme is a detergent enzyme, such as a protease, lipase, cellulase, amylase, or oxidase.

25

4. The method of claim 2, wherein said enzyme is a process enzyme, such as an amylase, lyase, lipase, or cellulase.

30

5. The method of claim 1, wherein said protein is a medicinal protein, such as a hormone, or medicinal enzyme.

6. A protein variant produced by the method of any of the claims 1 to 5.

35

7. The protein variant of claim 6, selected from the group comprising industrial enzymes, such as detergent enzymes, e.g. proteases, lipases, cellulases, amylases, or

oxidases, process enzymes, e.g. amylases, lyases, lipases, or cellulases.

8. The protein variant of claim 7, wherein said protein
5 is a protease.

9. The protease variant of claim 8, wherein said pro-
tease is a subtilisin protease.

10 10. The protease variant of claim 9, representing a va-
riant of a parent enzyme selected from subtilisin BPN',
subtilisin amylosacchariticus, subtilisin 168, subtilisin
mesenteropeptidase, subtilisin Carlsberg, subtilisin DY,
subtilisin 309, subtilisin 147, thermitase, aqualysin, Bacil-
15 lus PB92 protease, proteinase K, Protease TW7, and Protease
TW3.

11. The protease variant of claim 10, wherein the parent
enzyme is subtilisin 309.

20 12. The protease variant of claim 10, wherein the parent
subtilisin is subtilisin 147.

13. The protease variant of claim 10, wherein the parent
25 subtilisin is subtilisin Carlsberg.

14. The protease variant of claim 10, wherein the parent
subtilisin is Bacillus PB92 protease.

30 15. A subtilisin protease variant, wherein the immunologi-
cal potential has been changed in comparison to the parent
protease, for example in that, in said protease changes have
been performed among the amino acid residues at any one or
more of positions

35 127, 128, 129, 130, 131, 136, 151, 152, 153, 154, 161, 162,
163, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 186,
193, 194, 195, 196, 197, 247, 251, 261,

by deletion, substitution, or insertion (single or multiple) adjacent to the indicated positions, whereby said subtilisin protease has an immunological potential lower than that of said parent protease.

5

16. The protease variant of any of the claims 8 to 15, characterised in that it possesses at least one mutation affecting an amino acid residue occupying a position chosen from the group of positions

10 127, 151, 152, 153, 154, 168, 169, 173, 174, 175, 176, 193, 196.

17. The protease as claimed in any preceding claim, further characterised in that it contains at least one or 15 more sets of mutations affecting amino acid residues occupying a position chosen from the group of sets of positions:

36+209, 89+120, 136+170, 120+235, 170+195, 36+89, 89+235, 136+195, 181+222, 195+251, 209+222, 235+251.

20

18. The protein variant of claim 6, selected from the group comprising medicinal proteins, e.g. hormones, e.g. insulin, HCG, or growth hormone.

25 19. The protein variant of claim 6, selected from the group comprising medicinal enzymes, e.g. factor V, factor VII, factor VIII, or other proteins, e.g. interleukins, or interferons.

30 20. A composition comprising any protein variant according to any of claims 6 to 19.

21. The composition of claim 20, wherein said composition is a detergent compositions.

35

22. The composition of claim 20, wherein said composition is a compositions for use in preventive and/or

alleviating therapy and/or diagnosis of various conditions in the animal body, including man.

23. Use of a protein or composition according to any of 5 the claims 6 to 22 in detergents or for preventive and/or alleviating therapy and/or diagnosis of various conditions in the animal body, including man.

REPLACEMENT SHEET

1/3




FIG. 1




FIG. 2

2/3




FIG. 3




FIG. 4

3/3




FIG. 5




FIG. 6

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

Attorney's Docket Number:
3556.204-US

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this applications is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT
UNDER 35 U.S.C. 120:

U.S. APPLICATIONS

STATUS (Check one)

U.S. APPLICATION NUMBER	U.S. FILING DATE	Patented	Pending	Abandoned

PCT APPLICATIONS DESIGNATING THE U.S.

APPLICATION NO.	FILING DATE	US SERIAL NUMBERS ASSIGNED (if any)		
PCT/DK91/00382	5 December 1991 (05.12.91)		X	

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Steve T. Zelson, Esq.
Reg. No. 30,335

Elias J. Lambiris, Esq. Cheryl H. Agris
Reg. No. 33,728 Reg. No. 34,086

Send Correspondence to: Steve T. Zelson, Esq.

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6200
New York, New York 10017

Direct Telephone Calls To:

Steve T. Zelson
(212) 867-0123

1	Full Name of Inventor	Family Name Loevborg	First Given Name Uffe	Second Given Name
	Residence & Citizenship	City Ballerup	State or Foreign Country Denmark	Country of Citizenship Denmark
	Post Office Address	Post Office Address Grantofteparken 60	City Ballerup	State & Zip Code/Country DK-2750
2	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
3	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
Uffe Loeborg 01/10/93		